Table 3.
Risk for primary and secondary endpoints according to selected subgroups of study patients.
| NACCE | MACCE | Clinically significant bleeding | ||||
|---|---|---|---|---|---|---|
| Variables | Adjusted HR (95% CI) | P for interaction | Adjusted HR (95% CI) | P for interaction | Adjusted HR (95% CI) | P for interaction |
| Age, years | 0.807 | 0.321 | 0.451 | |||
| ≥75 | 0.77 (0.35 to 1.69) | 1.93 (0.63 to 5.95) | 0.22 (0.06 to 0.88) | |||
| <75 | 0.88 (0.66 to 1.19) | 1.02 (0.73 to 1.41) | 0.53 (0.29 to 0.98) | |||
| Gender | 0.146 | 0.205 | 0.224 | |||
| Male | 0.72 (0.52 to 1.01) | 0.91 (0.62 to 1.33) | 0.40 (0.19 to 0.83) | |||
| Female | 1.28 (0.77 to 2.12) | 1.76 (0.97 to 3.19) | 0.55 (0.21 to 1.39) | |||
| BMI, kg/m2 | 0.631 | 0.375 | 0.363 | |||
| >30 | 0.58 (0.19 to 1.82) | 1.71 (0.39 to 7.48) | 0.33 (0.05 to 2.12) | |||
| ≤ 30 | 0.88 (0.66 to 1.17) | 1.03 (0.74 to 1.42) | 0.49 (0.27 to 0.88) | |||
| Diabetes mellitus | 0.648 | 0.287 | 0.558 | |||
| Yes | 0.76 (0.48 to 1.18) | 0.82 (0.50 to 1.35) | 0.54 (0.21 to 1.37) | |||
| No | 0.89 (0.63 to 1.27) | 1.21 (0.80 to 1.83) | 0.40 (0.20 to 0.82) | |||
BMI, body mass index; MACCE, adverse clinical and cerebral events; NACCEs, net adverse clinical and cerebral events.